Background Although the indirect thrombin inhibitor heparin and the more potent direct inhibitor hirudin are useful in preventing thrombosis, a substantial opportunity remains for improving the thrombus selectivity of thrombin inhibitors.
Methods and Results To explore the effect of targeting an antithrombin to the surface of a clot, we covalently linked recombinant hirudin to the Fab' (or IgG) of a monoclonal antibody (59D8) that selectively binds to an epitope on fibrin that becomes exposed only after thrombin cleaves fibrinopeptide B. Antibody-coupled hirudin bound to an immobilized peptide of the fibrin ,3-chain amino-terminal sequence and inhibited the peptidolytic activity of thrombin more efficiently than free hirudin. Thrombin inhibition dependent on binding to immobilized fibrin monomer was enhanced 1100-fold (P<.0001). Hirudin-59D8 Fab' was 10 times more effective sing plasminogen activators to recanalize oc-U § cluded coronary arteries significantly reduces mortality in patients suffering from acute myocardial infarction.1-3 Nonetheless, thrombolytic therapy is still limited by the relative resistance of arterial clots to lysis4 and a high rate of thrombotic reocclusion.5 Acute thrombotic reocclusion is also an important setback after otherwise successful percutaneous transluminal coronary angioplasty,6 and it constitutes a formidable problem after the placement of intracoronary stents. 7 Adjunctive therapy with the currently available antiplatelet3 and anticoagulant8 agents has shown only modest benefit in preventing rethrombosis after thrombolytic therapy, and there is as yet no clinically validated therapeutic approach to restenosis after angioplasty.
Thrombin plays a central role in the development of arterial clots as the generator of fibrin and, perhaps more importantly, as the most potent activator of platelets. Heparin, which inhibits thrombin indirectly by activating antithrombin III, has been shown in experimental studies to have only a limited antagonistic effect on the action of thrombin. Recently, a number of direct inhibitors of thrombin, such as hirudin, have been shown to be more effective than heparin in preventing platelet-dependent arterial thrombosis and rethrombosis after thrombolytic reperfusion in animals.9-13 The underlying mechanisms for their greater efficacy include the susceptibility of clot-bound thrombin to inactivation by inhibitors independent of antithrombin III and the resistance of these antithrombin Ill-independent inhibitors to endogenous inactivators.14, 15 We previously reported that plasminogen activators targeted to the site of a thrombus by conjugation to an antifibrin or antiplatelet antibody have greatly enhanced thrombolytic potency and specificity in vitro and in vivo. [16] [17] [18] [19] [20] Because of the thrombus selectivity of these antibody-targeted plasminogen activators and the diminished fibrinogen consumption they induce,19 '20 split products that result from the proteolysis of fibrinogen by nonselective plasminogen activators (such as streptokinase) would probably be produced in smaller amounts. These fibrinogen split products, which have an anticoagulant effect, are believed to confer some protection against rethrombosis after streptokinase therapy. A thrombus-targeted anticoagulant would be a useful adjunct for preventing rethrombosis should a highly selective plasminogen activator be used in thrombolytic therapy. Also, a targeted anticoagulant would offer the potential of effecting thrombin inhibition in the vicinity of a thrombus without altering systemic homeostatic parameters.
In the present study, we evaluate the relative effects of hirudin and conjugates composed of hirudin and an antifibrin antibody or hirudin and the Fab' of that antibody. The antibody, 59D8, binds selectively to the new amino terminus of the fibrin 13-chain that becomes exposed after thrombin cleaves fibrinopeptide B.21 Because exposure of this epitope is an early event in the conversion of fibrinogen to fibrin, it is likely that the fibrin-targeted antithrombin conjugate would accumulate at the very site of thrombin action.
Methods

Materials
Recombinant hirudin (r-hirudin LU 52369, with a specific activity of 17 000 antithrombin units (ATU)/mg) was a gift from Knoll AG. The preparation and purification of monoclonal antifibrin antibody 59D8 have been described. '6,21 The synthetic peptides B13 (15) (16) (17) (18) (19) (20) (21) 
Preparation of Hirudin-59D8 IgG Conjugate
Disulfide-linked hirudin-IgG conjugate was prepared by reacting an SPDP derivative of hirudin with 2-iminothiolanesubstituted antibody 59D8. Hirudin (8 mg, supplied freezedried) was dissolved in 2 mL of 50 mmol/L sodium carbonate buffer (pH 8.5), and 2 mL of n-propanol was added to the solution. SPDP in a threefold molar excess (20 mmol/L in absolute ethanol) was added dropwise to the solution, and the mixture was stirred gently at room temperature for 30 minutes, after which it was applied to a Sephadex G-25 column (1.6 x90 cm) equilibrated with PBS (0.1 mol/L NaH2PO4 and 0.1 mol/L NaCl, pH 7.4). Peak protein fractions were pooled and analyzed for 2-pyridyldisulfide content,22 which typically showed 0.6 to 1.5 residues per hirudin molecule. The substitution level was intentionally kept low to limit the loss of hirudin activity and to avoid the formation of higher-molecular-weight aggregates. The specific activity of SPDP-modified hirudin was on average 53% that of unmodified hirudin.
Antifibrin antibody 59D8 (4 mg/mL in 0.14 mol/L NaCl, 3 mmol/L sodium arsenate, followed by the addition of solid Ellman's reagent to a concentration of 5 mmol/L. After 3 hours at room temperature, excess reagent was removed from the mixture by gel filtration on a Sephadex G-25 column (30x2 cm) equilibrated with 0.1 mol/L sodium phosphate (pH 6.8). In this protected form, 59D8 Fab' has remained structurally and functionally intact under sterile conditions at 4°C for at least a year.
The thiol form of 59D8 Fab' was regenerated by treatment with 10 mmol/L 2-mercaptoethylamine for 30 minutes at room temperature, followed by gel filtration. The thiol form (at 1 mg/mL) was then mixed with SPDP-modified hirudin (1 mg/mL) and allowed to react for 16 hours at room temperature. To minimize the amount of uncoupled 59D8 Fab' in the final preparation, we maintained a 10-fold molar excess of hirudin in the mixture. The reaction was stopped by the addition of an excess of iodoacetamide, as described above.
Purification of Hirudin-59D8 Conjugates
Hirudin-59D8 IgG conjugate and hirudin-59D8 Fab' conjugate were both partially purified from their reaction mixtures by affinity chromatography on a 13-peptide-Sepharose column (lysine-Sepharose to which the 13-peptide, against which antibody 59D8 had been raised, was coupled through a cysteine residue with MBS). The P-peptide-Sepharose column retained conjugate and unconjugated 59D8 IgG (or 59D8 Fab') but not uncoupled hirudin. 
Measurement of Thrombin Inhibition by Hirudin and Hirudin-Antibody Conjugates (S-2238 Assay)
The proteolytic activity of thrombin can be measured by cleavage of the peptide substrate S-2238, which results in a colored product that can be quantified by reading absorbance at 405 nm. The inhibitory effect (on the activity of thrombin) of hirudin or hirudin-antibody conjugate can then be determined as a function of the degree of inhibition of S-2238 cleavage.
In the S-2238 assay, 20 ,L of thrombin solution (2.5 U/mL water) was added to 100 ,L of sample (hirudin or hirudin-59D8 conjugate) in assay buffer (20 standard. A decrease in absorbance was linearly related to hirudin concentrations in the range of 0 to 0.6 U/mL. Samples showing higher activity were diluted so that they could be measured within this range.
f3-Peptide Assay
This assay was used to compare the activities of hirudin and hirudin-antibody conjugate bound to microtiter plates that had been coated with ,B-peptide. The assay also measures inhibition of S-2238 cleavage by thrombin, although in this instance the inhibitor is bound to the plastic of the microtiter plate instead of being in solution. 
Fibrin-Sepharose Assay
The purpose of this assay was to compare the activities of hirudin and hirudin-antibody conjugate bound to fibrin monomer covalently linked to Sepharose. The preparation of fibrinSepharose has been described.17 Like the assay described above, the fibrin-Sepharose assay also measures inhibition of S-2238 cleavage by thrombin, although in this instance the inhibitor is bound to immobilized fibrin monomer.
Fibrin-Sepharose (200,uL) was incubated for 2.5 hours at room temperature with measured aliquots (by S-2238 assay) of hirudin or hirudin-59D8 conjugate (IgG or Fab) in 100 ALL of buffer. The fibrin-Sepharose was washed three times with 3 mL of 0.15 mol/L NaCl, and then 200,.L of S-2238 assay buffer and 40,uL (0.05 U) of thrombin solution (1.25 U/mL) was added to the mixture and allowed to incubate for 1 hour at room temperature. Chromogenic substrate S-2238 (100 juL) was added, and the reaction was stopped after 25 minutes by the addition of 100,uL of 20% acetic acid. After centrifugation for 5 minutes at1000g, absorption of the supernatant was read at 405 nm. The inhibitory activity of hirudin was expressed in terms of inhibition of thrombin activity.
Inhibition of Thrombus Growth in a Fibrinogen Solution
This assay was used to compare the effectiveness of hirudin and hirudin-antibody conjugate in the inhibition of fibrin deposition on the surface of a plasma clot immersed in a fibrinogen solution. We followed the method of Runge et a126 with some modification. Fresh-frozen plasma from five donors was pooled, divided into aliquots, and refrozen. Before each experiment, plasma was ultracentrifuged at 30000 rpm for 60 minutes in a Beckman SW 40 rotor to obtain platelet-free plasma (<1000 platelets/lL). Immediately before each experiment, inhibition of thrombin peptidase activity by hirudin and the hirudin conjugate was determined, and appropriate dilutions were made so that inhibition of thrombin peptidase activity was identical for each experimental point. Platelet-free plasma clots were made by adding to plasma, in the following sequence, '251-labeled human fibrinogen (20 000 cpm/mL plasma), 0.5 mol/L CaCl2 (0.05 mol/L final concentration), and thrombin (0.5 NIH units/mL plasma). Immediately after the addition of thrombin, the solution was drawn into Silastic tubing (4-mm ID) and allowed to clot for 2 hours at 37°C. The tubing was then cut into 1.8-cm sections to yield clots of about 0.2 mL. The clots were removed from the tubing, and each was placed in a plastic vial and washed three times with 2 mL of 0.15 mol/L NaCl. 1251-radioactivity was measured in a gamma counter, and only clots within 5% of the mean count value were used in the experiments.
The clots were then resuspended in 100 ,uL of TBS (0.1 mol/L Tris and 0.1 mol/L NaCI, pH 7.4). Experiments were initiated by the addition of 100 ,uL hirudin (or conjugate) solution for which inhibition of thrombin peptidase activity had been determined. Then 200 ,uL fibrinogen solution (8 mg/mL) trace-labeled with 125I-fibrinogen (250 000 cpm/mL) was added. The final fibrinogen concentration in the assay was 4 mg/mL (within the physiological range). At predetermined intervals, clots were removed from the test tubes and washed three times with 2 mL of 0.15 mol/L NaCl, and radioactivity was measured in a gamma counter. Clots incubated without thrombin inhibitor (the NaCI controls) often adhered tightly to the wall of the test tube and could not be removed completely.
Inhibition of Thrombus Growth in Human Plasma In Vitro
In this assay, which was carried out essentially as described in the preceding section, clots were incubated with 200 ,uL of platelet-free plasma (instead of 200,uL of fibrinogen solution) that had been trace-labeled with 1251-fibrinogen (250 000 cpm/mL).
Measurement of Fibrinopeptide A in Human Plasma
In some experiments, the inhibition of thrombus growth in human plasma was followed as described above, and the concentration of fibrinopeptide A was measured in the plasma supernatant. At various times, thrombin activity was stopped by the addition of hirudin (100 ATU in 100,uL) to the plasma (to a total volume of 500 pL). This plasma solution (100 ALL) was then used, after an appropriate dilution with 0.9% NaCl, to determine the amount of fibrinopeptide A by ELISA (ELISA-FPA, Boehringer Mannheim). We followed the manufacturer's instructions exactly.
Statistical Analysis
The dose-response curves in Hirudin is sensitive to SPDP modification because an intact lysine-47 is essential for its effect as an antithrombin. Since the pK of the E-amino group is higher than that of the a-amino group at the amino terminus, a reaction pH higher than the pK of the e-amino group would favor the reaction of SPDP with the amino terminus (Dr Schweden, BASF, personal communication). Therefore, we intentionally kept the concentration of SPDP low so as not to introduce more than one reactive group into the hirudin molecule. Nevertheless, SPDP-hirudin was on average only 53% as active as unmodified hirudin (17 000 ATU) in inhibiting thrombin in the S-2238 assay.
The parent molecules and products of the synthesis of hirudin-59D8 Fab' were analyzed by SDS-PAGE. Under nonreducing conditions, hirudin-59D8 Fab' could be visualized at the anticipated molecular size of about 57 kD. The thrombin-inhibitory activity of hirudin was compared with that of hirudin-59D8 IgG conjugate (or hirudin-59D8 Fab' conjugate) in the absence of the target molecule (fibrin) by measuring inhibition of thrombin peptidase activity. Thrombin-dependent cleavage of chromogenic substrate S-2238 was recorded at 405 nm. In subsequent experiments, appropriate dilutions of hirudin, hirudin-59D8 IgG, and hirudin-59D8 Fab' were used so that inhibition of thrombin peptidase activity was identical for each experimental point. Thrombin Inhibition as a Function of Hirudin Binding to /3-Peptide Since hirudin does not bind specifically to the amino terminus of fibrin, we were not surprised by the results in Fig 1A, which show that, at equivalent initial thrombin-inhibitory concentrations, ultimate percent inhibition for the hirudin-59D8 IgG conjugate was 12-fold greater than that for hirudin in an assay that depends on binding to the /8-peptide (B1, 55+2% versus 4.3+0.5%, 
Inhibition of Thrombus Growth in Fibrinogen Solution
Fig 3 compares fibrin deposition on the surface of a plasma clot suspended in fibrinogen solution in the presence of hirudin with that in the presence of hirudinIgG conjugate. Because interassay variability is quite large with this test, we made intra-assay comparisons whenever possible. Conjugate at 7.4 ATU/mL was indistinguishable from hirudin at 80 ATU/mL in allowing deposition of fibrin (at a mean of 13 ,ug less deposition than hirudin) (Fig 3A) . Conjugate at 7.4 ATU/mL allowed significantly less fibrin deposition than hirudin at 8 ATU/mL (233 ,ug less, P=.0002) and hirudin at 2.4 ATU/mL (252 gg less, P=.0001). Conjugate at 1.2 ATU/mL allowed significantly more fibrin deposition than hirudin at 80 ATU/mL (113 ,ug more, P=.01). The other comparisons were not significant.
When fibrin deposition was plotted against inhibition of thrombin peptidase activity, hirudin-59D8 IgG conjugate was about 10 times more effective than hirudin (Fig 3B) . Fibrin deposition at 1.0 ATU/mL [the constant in the linear regression of fibrin deposition versus ln(ATU/mL)] for hirudin-59D8 IgG was significantly lower than that for unconjugated hirudin (P= .003). The slopes were not different.
Results for hirudin-59D8 Fab' were similar (Fig 4) . Fibrin deposition for hirudin-59D8 Fab' at 9.25 ATU/mL was 21 ,ug lower than that for hirudin at 100 ATU/mL (P=.001), 71 ,gg lower than that for hirudin at 30 ATU/mL (P=.0001), and 129 ,g lower than that for hirudin at 10 ATU/mL (P=.0001) (Fig 4A) . Also, fibrin deposition for hirudin-59D8 Fab' at 3 ATU/mL was significantly lower, by 74 jig, than that for hirudin at 10 ATU/mL (P=.01). All other fibrin deposition curves were indistinguishable. For the dose-response curves (Fig 4B) , the fibrin deposition at 1.0 ATU/mL for hirudin-59D8 Fab' was significantly lower than that for unconjugated hirudin (P=.003); the slopes were equal.
Inhibition of Thrombus Growth in Human Plasma In Vitro
We then determined whether the enhanced potency of hirudin-59D8 Fab' could also be demonstrated in human plasma. Fig 5A shows (Fig 6A) generally paralleled inhibition of the formation of fibrinopeptide A (Fig 6B) . When 3 U hirudin was added, there was a significant inhibition of both fibrin deposition and fibrinopeptide A generation in comparison with the saline control. Three units of conjugate resulted in nearly complete inhibition of both fibrin deposition and fibrinopeptide A generation (P=.0001). cations, antibody-targeted hirudin is likely to concentrate hirudin activity at sites of thrombosis. Because the hirudin would be concentrated at the thrombus, the plasma concentration of hirudin required for anticoagulation could be lower. As a consequence, it would be possible to anticipate fewer hemorrhagic complications.
Comparison of Hirudin
If studies in animal models continue to show the promise of these in vitro observations, the construction of a recombinant fusion protein between hirudin and the antibody would be of value. In our previous studies of antibody-plasminogen activator conjugates, the behavior of a specific chemical conjugate often predicted that of a recombinant fusion protein. 19 .27 It follows that fusion proteins could also be constructed from other antithrombins (such as anti-factor Xa) and other thrombus-directed antibodies (such as those to epitopes on the platelet surface). Clinical applications could include any situation in which the therapeutic aim is localized inhibition of thrombosis as contrasted with systemic anticoagulation.
